CONEXEU SCIENCES INC
CNXUNASDAQ🏆 #3120 by market capEarnings Sep 30US Equity
$7.44▲ $0.17 (+2.34%)
🌅 Pre-market$7.28▼ 2.13%Regular close · extended-hours price shown1h—
24h▲ 2.3%
7d▼ 19.0%
14d▼ 6.0%
30d▼ 27.3%
1y—
🏦Market Cap
$199M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
66
Fair
Trading Snapshot
- Day Range
- $7.38 – $7.54
- 52-Week Range
- $7.06 – $18.79
- Volume
- $2.61B
- Avg Volume
- $2.88B
- Shares Outstanding
- 26.8M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $30M
- Last Q Revenue
- $8M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own CNXU
- ✓High-growth profile — revenue up +55.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$30M▲ +48.3% YoY
Gross Margin (TTM)
29.5%▲ +0.5% YoY
Operating Income (TTM)
$3M▲ +48.3% YoY
Free Cash Flow (TTM)
$6M▲ +48.3% YoY
About CONEXEU SCIENCES INC
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
66/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
